Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02630615 · ClinicalTrials.gov registry record
Circulating Tumor Cells (CTC) in Lung Cancer
A clinical trial of Lung Neoplasms, sponsored by Shadia Jalal.
- Recruiting
- Registry status
- 80
- Enrollment target
- 2
- Study locations
NCT02630615 is a study of Lung Neoplasms that is actively recruiting participants, run by Shadia Jalal. The registered enrollment target is 80 participants, below the 463-participant average among 22 other Lung Neoplasms trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02630615, a study of Lung Neoplasms, is actively recruiting participants, sponsored by Shadia Jalal.
- RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective of this study is to establish circulating tumor cell (CTC) derived xenografts and assess the activity of novel DNA repair inhibitors as a function of DNA repair mutations detected in CTC samples (personalize DNA repair therapy).
Conditions Studied
Interventions
- OTHER Blood draw
Study Locations (2)
Indiana
- Indiana University Health Melvin and Bren Simon Cancer Center - Indianapolis
- Roudebush VA Medical Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2017-10-19 |
| Est. Completion | 2026-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02630615
The ClinicalTrials.gov registry entry for NCT02630615 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 463-participant average among 22 other Lung Neoplasms trials with a reported enrollment target (83% lower). The listed sponsor is Shadia Jalal, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Blood draw is the first listed.
NCT02630615 reports 2 study locations spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT02630615 about?
NCT02630615 is a clinical study titled "Circulating Tumor Cells (CTC) in Lung Cancer". The primary objective of this study is to establish circulating tumor cell (CTC) derived xenografts and assess the activity of novel DNA repair inhibitors as a function of DNA repair mutations detected in CTC samples (personalize DNA repair therapy).
What is the current status of trial NCT02630615?
This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2017-10-19. Estimated completion is 2026-10.
What conditions does trial NCT02630615 study?
This clinical trial studies the following conditions: Lung Neoplasms.
What interventions are being tested in trial NCT02630615?
The interventions under investigation include: Blood draw (OTHER).
Who is sponsoring clinical trial NCT02630615?
This trial is sponsored by Shadia Jalal, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02630615 being conducted?
This trial has 2 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
Specimen Banking From Patients With Lung Cancer
RECRUITING
-
TELESCOPE- TELEhealth Shared Decision-making COaching
RECRUITING · NA
-
TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics
RECRUITING · NA
-
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.